Sorted By Test Name - Mayo Medical Laboratories

FELBA
80782
FESE
82363
Negative
This test has not been validated in a pediatric population, results should be interpreted in the context of
the patient's presentation.
Clinical References: 1. Levin B, Lieberman DA, McFarland B, et al: Screening and Surveillance for
the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the
American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American
College of Radiology. CA Cancer J Clin 2008;58:130 2. Whitlock EP, Lin JS, Liles E, et al: Screening for
colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann
Intern Med 2008;149:638 3. Hol L, Wilschut JA, van Ballegooijen M, et al: Screening for colorectal
cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off
levels. Br J Cancer 2009;100:1103 4. Levi Z, Rozen P, Hazazi R, et al: A quantitative immunochemical
fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244 5. Tannous B,
Lee-Lewandrowski E, Sharples C, et al: Comparison of conventional guaiac to four immunochemical
methods for fecal occult blood testing: implications for clinical practice in hospital and outpatient settings.
Clin Chem Acta 2009;400:120-122
Felbamate (Felbatol), Serum
Clinical Information: Felbamate is an anticonvulsant drug approved for treatment of partial seizures
with or without secondary generalization in persons >14 years of age. It is also approved for
Lennox-Gastout syndrome in children >2 years of age. Felbamate is well absorbed (>90%) and is
metabolized by the hepatic cytochrome P450 system. Metabolites lack anticonvulsant activity. The
elimination half-life of felbamate ranges from 13 to 23 hours. Optimal response to felbamate is seen with
serum concentrations between 30 mcg/mL to 60 mcg/mL. Patients who are elderly or have renal
dysfunction may require reduced dosing; felbamate should not be given to individuals with hepatic
disease. Toxicity can be severe, including life-threatening aplastic anemia or liver failure, but no defined
toxic concentration has been established. Coadministration of felbamate increases the concentration of
phenytoin and valproic acid, decreases carbamazepine concentration, and increases
carbamazepine-10,11-epoxide (its active metabolite). Conversely, coadministration of phenytoin or
carbamazepine causes a decrease in felbamate concentration.
Useful For: Determining whether a poor therapeutic response is attributable to noncompliance or lack
of drug effectiveness Monitoring changes in serum concentrations resulting from interactions with
coadministered drugs such as barbiturates and phenytoin
Interpretation: Optimal response to felbamate is associated with serum concentrations of 30 mcg/mL
to 60 mcg/mL. Toxic serum concentrations for felbamate have not been established.
Reference Values:
30.0-60.0 mcg/mL
Clinical References: 1. Johannessen, SI, Tomson, T: Pharmacokinetic Variability of Newer
Antiepileptic Drugs: When is Monitoring Needed? Clin Pharmacokinet 2006; 45 (11): 1061-10752.
Schmidt D: Felbamate: successful development of a new compound for the treatment of epilepsy.
Epilepsia 1996;34(Suppl 7):S30-S33 2. Patsalos PN: Antiepileptic drugs--best practice guidelines for
therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring,
ILAE Commission on Therapeutic Strategies. Epilepsia. 2008 Jul;49(7): 1239-1276
Fennel Seed, IgE
Clinical Information: Clinical manifestations of immediate hypersensitivity (allergic) diseases are
caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from
immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE
antibodies interact with allergen. In vitro serum testing for IgE antibodies provides an indication of the
immune response to allergen(s) that may be associated with allergic disease. The allergens chosen for
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 735